Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LT-011
- Development stage
- Preclinical
- Lead developer
- lncTAC Bio
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
LT-011 is a preclinical-stage, long non-coding RNA (lncRNA)-based therapeutic candidate being developed by Chengdu Lingtaike Biotechnology (LNCTAC). It is designed as a pan-tumor delivery platform utilizing lncRNA-mediated toxin delivery for oncology indications. The drug leverages LNCTAC's proprietary lncRNA-based targeting chimera (lncTAC) and UNAST platforms to achieve targeted delivery and stability of nucleic acid therapeutics. LT-011 is currently in the preclinical/lead optimization stage of development.
Beyond the preview
Go deeper on LT-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LT-011.